Lumos Pharma, Inc. (LUMO)

Market Cap	29.15M
Revenue (ttm)	1.23M
Net Income (ttm)	-28.46M
Shares Out	8.38M
EPS (ttm)	-3.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,590
Open	3.44
Previous Close	3.46
Day's Range	3.42 - 3.71
52-Week Range	2.95 - 10.27
Beta	0.70
Analysts	Buy
Price Target	20.91 (+500.86%)
Earnings Date	Mar 8, 2023

About LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: LUMO

Financial Performance

In 2021, Lumos Pharma's revenue was $230,000, an increase of 36.90% compared to the previous year's $168,000. Losses were -$30.43 million, 381.9% more than in 2020.

Analyst Forecast

According to 12 analysts, the average rating for LUMO stock is "Buy." The 12-month stock price forecast is $20.91, which is an increase of 500.86% from the latest price.

Price Target

$20.91

(500.86% upside)

Analyst Consensus: Buy